NCT05078866View on ClinicalTrials.gov

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

April 16, 2025

Study Completion Date

September 30, 2026

Conditions
Colorectal CarcinomaLynch Syndrome
Interventions
BIOLOGICAL

Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP

Given IM

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Endoscopic Biopsy

Undergo endoscopy with biopsy

BIOLOGICAL

MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP

Given IM

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

00936

University of Puerto Rico, San Juan

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH